Developing better methods to compare cancer treatments using real-world data
Robust Causal Comparisons of Nonrandomized Oncology Studies
['FUNDING_R21'] · GEORGETOWN UNIVERSITY · NIH-10614590
This study is looking at how well new cancer treatments work compared to existing ones by using real patient data, so we can better understand which therapies help people live longer and stay cancer-free, even when traditional testing isn't possible.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGETOWN UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-10614590 on ClinicalTrials.gov |
What this research studies
This research focuses on creating advanced statistical models to compare the effectiveness of cancer treatments when traditional randomized controlled trials are not possible. By utilizing real-world data, such as electronic health records, the study aims to assess how new therapies perform against existing treatments in patients with various types of cancer. The researchers will specifically look at survival rates and relapse-free survival in patients receiving different therapies, ensuring that the methods used are robust and reliable for making causal inferences about treatment efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with malignant neoplasms who are receiving or have received various cancer therapies and for whom randomized trials are not feasible.
Not a fit: Patients who are not diagnosed with cancer or those who are currently enrolled in traditional randomized clinical trials may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate assessments of cancer treatments, ultimately improving patient outcomes and survival rates.
How similar studies have performed: Other research has shown promise in using real-world data for causal comparisons in oncology, indicating that this approach has potential for significant advancements in treatment evaluation.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGETOWN UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TAN, MING TONY — GEORGETOWN UNIVERSITY
- Study coordinator: TAN, MING TONY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer